At ESCRS 2025, VSY Biotechnology GmbH highlighted its latest innovations in premium intraocular lenses (IOLs), demonstrating its continued leadership in vision care solutions. Kathrin Brokelmann, Global Marketing Manager at VSY Biotechnology GmbH, shared insights into the company’s featured technologies, perspectives on the evolving needs of ophthalmologists, and strategic vision for the global market.
Highlighting Innovation: The Enova® Advanced and Enova Maestro®
At the ESCRS 2025 exhibition, VSY Biotechnology GmbH focused on showcasing the Enova® Family, particularly the Enova Advanced and Enova Maestro® lenses. According to Brokelmann, both IOLs are crafted from proprietary glistening-free hydrophobic acrylic material, offering long-term optical clarity and stability.
“The Enova® Advanced is designed to offer an extended range of vision with excellent contrast sensitivity,” said Brokelmann. “It enables patients to enjoy greater spectacle independence in everyday life.”
Meanwhile, the Enova Maestro® introduces the company’s Sinusoidal Trifocal Technology, a unique optical design that distributes light energy efficiently, enhancing visual quality across near, intermediate, and distance ranges.
“The Maestro® provides smooth visual transitions and minimizes visual disturbances like halos and glare,” she explained.
Both lenses underscore VSY Biotechnology GmbH’s commitment to merging advanced optical engineering with surgeon-friendly design and patient-centered outcomes.
Understanding Evolving Surgeon Needs
As surgical techniques and patient expectations evolve, so do the needs of ophthalmologists. Brokelmann noted that predictability, safety, and lifestyle customization are now top priorities for eye surgeons.
“Ophthalmologists increasingly demand IOL solutions that are predictable, safe, and tailored to patient lifestyles. As expectations for premium outcomes rise, surgeons seek lenses that deliver not only a broad range of vision but also superior contrast and reduced dysphotopsia,” she said. “Additionally, with surgical volumes and patient diversity growing, ease of handling, consistent performance, and advanced materials—such as glistening-free hydrophobic acrylics—are becoming essential."
Strategic Vision: Expanding Global Impact
Looking ahead, VSY Biotechnology GmbH is positioning the Enova® Family as a leading global portfolio of premium intraocular lenses. The company aims to drive growth through a combination of technological innovation, strategic partnerships, and global expansion.
“By integrating cutting-edge optical concepts such as Sinusoidal Trifocal Technology with high-quality, glistening-free materials, we aim to set new standards in optical performance and patient satisfaction," said Brokelmann.
The company plans to continue investing in research and development, strengthening collaboration with ophthalmic professionals, and building its international footprint.
“Our overarching goal is to establish VSY Biotechnology GmbH as a trusted innovation partner worldwide synonymous with clarity, precision, and excellence in vision care."
VSY Biotechnology GmbH’s presence at ESCRS 2025 reflects not only its technical capabilities but also its strategic intent to shape the future of premium IOL solutions globally. With its focus on innovation, quality, and collaboration, the company continues to evolve as a key player in the global ophthalmic landscape.
